RS Research

RS Research is a clinical-stage biotechnology start-up headquartered in Turkey that is at the forefront of developing smart nanomedicines for targeted chemotherapy. Established in 2015, the company leverages its innovative drug delivery platform, Sagitta®, aiming to provide a “Cure With a Smile” through an enhanced therapeutic index for patients battling cancer.

Focusing within the Biotechnology and Pharmaceutical industries, RS Research has demonstrated a strong pipeline by strategically intertwining scientific discovery with practical industry applications. The company’s last funding round was a $12.00M Series A investment in December 2021, backed by reputable investors including Gen Ilac, OneLife Ventures, Eczacıbasi Momentum, and Gen Pharmaceuticals. This investment underscores confidence in RS Research’s potential to revolutionize cancer treatment, positioning them as a promising venture for forward-thinking investors.